Table 3.
Case 1 | ||||||
---|---|---|---|---|---|---|
Time of use to illness: 6 mo**↓ | ||||||
| ||||||
Time of use to discontinuation: 6 mo**↓ | ||||||
| ||||||
Time of presentation to the liver clinic* | *↓ | |||||
| ||||||
Duration of illness in months | 2 | 4 | 7 | 12 | 15 | 40 |
Treatment | — | Prednisone | Azathioprine | — | — | — |
| ||||||
Liver function tests (normal) | ||||||
Total bilirubin (0.8–1.2 mg/dL) | 3.1 | 1.4 | 1.8 | 0.9 | 1.0 | 0.8 |
ALT (5–40 U/L) | 1457 | 334 | 321 | 30 | 39 | 37 |
AST (10–40 U/L) | 696 | 229 | 236 | 29 | 37 | 33 |
ALP (30–120 U/L) | 94 | 68 | 66 | 36 | 38 | 37 |
INR (0.8–1.2) | 1.2 | 1.17 | — | 0.95 | — | 0.92 |
| ||||||
Autoimmune antibodies | ||||||
Antinuclear antibody | 1 : 40 | 1 : 20 | — | — | — | — |
Antismooth muscle antibody | 1 : 80 | — | — | — | — | — |
Liver biopsy findings | — | Acute hepatitis | Chronic hepatitis | — | Biopsy at 15 mo. | |
| ||||||
Lobular | ||||||
Necrosis | — | Central & portal | — | — | Absent | |
Infiltrates | — | Mixed with eosinophils | Plasmacytic | — | Absent | |
Other findings | — | Disarray, ballooning Apoptosis | — | No significant abnormality | ||
| ||||||
Portal and periportal | ||||||
Cholangiolar proliferation | — | Moderate | Moderate | — | Absent | |
Infiltrate severity | — | Moderate | Moderate | — | Minimal | |
Infiltrate predominant type | — | Mixed with eosinophils | Plasmacytic | — | Lymphocytes | |
Fibrosis | — | Fibronecrosis | Fibronecrosis | — | Absent |